In the January to March period, the company's revenue from operations surged double-digit by 16% year-on-year (YoY) to ₹6,296.8.2 crore, up from ₹5,436.8 crore in the same period last year.
The portfolio includes 45 commercial products, four pipeline products and 40 approved non-marketed products, including many generic products, focused on women’s health
The Indian production facility of Mondelez, Dr. Reddy’s, and Cipla have joined WEF's Global Lighthouse Network
The Sensex and Nifty are set to open higher on the first day of September F&O contracts, tracking firm cues from global equities and positive trends on SGX Nifty Futures.
Dr. Reddy’s Laboratories has received the U.S. FDA approval to launch Fesoterodine Fumarate extended-release tablets in the American market
Revenue of the pharma company rose 15% year-on-year to ₹5,437 crore in the fourth quarter.
The BSE Sensex and the NSE Nifty are poised to open lower on Wednesday amid mixed global cues as well as growing Covid-19 cases surge across the country.
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.
The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
Prices of vaccines may crash in the next few months. The vaccine makers will have to strike while the iron is hot.
